The KRAS-variant and treatment response in BATTLE-1.

被引：2
|
作者：
Weidhaas, Joanne B.
Kim, Edward S.
Herbst, Roy S.
Yu, Jun
Slack, Frank
Blumenschein, George R.
Tsao, Anne S.
Wistuba, Ignacio Ivan
Lee, J. Jack
Papadimitrakopoulou, Vassiliki
Hong, Waun Ki
Heymach, John
Tran, Hai T.
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA
[3] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA
[4] MDACC, Houston, TX USA
[5] Yale Univ, New Haven, CT USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.8135
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8135
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The KRAS-variant and cetuximab response in RTOG 0522.
    Weidhaas, Joanne B.
    Harris, Jonathan
    Axelrod, Rita
    El-Naggar, Adel K.
    Singh, Anurag
    Galloway, Thomas
    Raben, David
    Wang, Dian
    Herman, Terence S.
    Lee, R. Jeffrey
    Manon, Rafael Ricardo
    Yumen, Omar
    Zhang, Qiang
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
    Weidhaas, Joanne B.
    Hu, Chen
    Komaki, Ritsuko
    Masters, Gregory A.
    Blumenschein, George R.
    Chang, Joe Y.
    Lu, Bo
    Dicker, Adam P.
    Bogart, Jeffrey A.
    Garces, Yolanda I.
    Narayan, Samir
    Robinson, Clifford G.
    Kavadi, Vivek S.
    Greenberger, Joel S.
    Koprowski, Christopher D.
    Welsh, James
    Gore, Elizabeth M.
    Macrae, Robert M.
    Paulus, Rebecca
    Bradley, Jeffrey D.
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (10): : 2074 - 2081
  • [3] Impacts of the KRAS-variant on breast cell biology
    Jung, Song-Yi
    Weidhaas, Joanne
    CANCER RESEARCH, 2016, 76
  • [4] A KRAS-variant as a biomarker of ovarian cancer risk
    Weidhaas, J. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] A KRAS-variant as a putative biomarker of ovarian cancer risk
    Weidhaas, Joanne B.
    Slack, Frank
    CANCER RESEARCH, 2010, 70
  • [6] Estrogen withdrawal, increased breast cancer risk and the KRAS-variant
    McVeigh, Terri P.
    Jung, Song-Yi
    Kerin, Michael J.
    Salzman, David W.
    Nallur, Sunitha
    Nemec, Antonio A.
    Dookwah, Michelle
    Sadofsky, Jackie
    Paranjape, Trupti
    Kelly, Olivia
    Chan, Elcie
    Miller, Nicola
    Sweeney, Karl J.
    Zelterman, Daniel
    Sweasy, Joann
    Pilarski, Robert
    Telesca, Donatello
    Slack, Frank J.
    Weidhaas, Joanne B.
    CELL CYCLE, 2015, 14 (13) : 2091 - 2099
  • [7] A 3′UTR KRAS-variant and triple negative breast cancer
    Paranjape, Trupti
    Weidhaas, Joanne B.
    CANCER RESEARCH, 2011, 71
  • [8] The KRAS-variant, multiple breast cancer risk, and estrogen withdrawal
    Weidhaas, Joanne B.
    Mcveigh, Terri
    Pilarski, Robert
    Miller, Nicola
    Sweasy, Joann
    Kerin, Michael
    Nallur, Sunitha
    Sadofsky, Jackie
    Nemec, Antonio
    Sweeney, Karl
    Daniel, Zelterman
    CANCER RESEARCH, 2015, 75
  • [9] Estrogen withdrawal and breast cancer development in the presence of the KRAS-variant
    Jung, Song-Yi
    Salzman, David
    Weidhaas, Joanne B.
    CANCER RESEARCH, 2015, 75
  • [10] The KRAS-variant induces an EMT in normal breast epithelial cells
    Jung, Song-Yi
    Salzman, David
    Nguyen, Kiana
    Pak, Ethan
    King, Joshua
    Nallur, Sunitha
    Weidhaas, Joanne
    CANCER RESEARCH, 2018, 78 (04)
12345